ArticleCureus2025
Evaluation of the Course and Outcome of Aggressive Retinopathy of Prematurity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study was conducted to evaluate the course and outcome of aggressive retinopathy of prematurity (AROP) and to study the risk factors associated with AROP. METHODOLOGY: This was a prospective observational study, conducted in the Department of Ophthalmology, Gandhi Medical College, Bhopal, India, from August 2022 to June 2024 on preterm infants. Infants were examined in the retinopathy of prematurity (ROP) screening cubicle using aseptic precautions. All ocular findings were recorded on the proforma, and any abnormal findings were confirmed by the study guide. In cases where ROP is detected, fundus photo documentation is done. Counselling of the parents was conducted, emphasizing the importance of timely follow-up and the need for periodic reviews.
resultsThe incidence of ROP was 24.9%, while the incidence of AROP was 10.5%. Overall, AROP was detected in 107 eyes of 56 patients. Zone I was most commonly involved in 58 eyes (54.2%), followed by posterior zone II in 49 eyes (45.8%). We documented a significant association of AROP with prolonged duration of stay in the neonatal intensive care unit (NICU) (18.20±10.21 vs. 13.17±6.35 days), oxygen supplementation of more than one week (87.5% vs. 68.4%), prolonged duration of oxygen supplementation (16.50±8.34 vs. 10.50±5.2), and ventilatory support of more than one week (16.1% vs. 3.9%; p<0.05). We found regression following treatment with anti-vascular endothelial growth factor (anti-VEGF) in significantly higher proportions of cases with zone I AROP and progression following anti-VEGF in cases with zone II posterior AROP (p<0.05).
conclusionsThe relatively high incidence of AROP, predominantly bilateral and affecting zone I, underscores the need for vigilant screening and early intervention in high-risk infants. Our findings reinforce the importance of minimizing exposure to supplemental oxygen and optimizing neonatal care practices to reduce the risk of AROP development and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.